

ICC APL STUDY 02

Treatment study for children and adolescents with APL


Open label, prospective multicenter trial

INTERNATIONAL SPONSOR: AIEOP

Plánovaná centra: Praha, Brno


- schváleno SÚKLEM, Etickou komisí FN Motol
- uzavřeno pojištění
- čekáme na podpis smlouvy mezi FN Motol a mezinárodním zadavatelem, následně proběhne iniciace studie ve FN Motol a předání všech podkladů do FN Brno

SR



Intrathecal therapy : 0

HR



Intrathecal therapy :
i.th. triplet at the beginning of the 1 st and 3rd course of consolidation therapy


R/R AML



Studie ITCC-101/APAL2020D


A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

(A subtrial of the PedAL/EuPAL relapsed acute leukemia master protocol)



Plánované otevření 9/2022
1 centrum v ČR FN Motol

Figure 2B. Treatment schema Arm B cycle 1 and cycle 2



FLT3 pozit. AML

Primární léčba:

studie s midostaurinem (CPKC412A2218), otevřena ve 2 centrech (Praha, Brno) – tč. pozastaven nábor do 10/22
dostupný je sorafenib

R/R AML:

ověřujeme dostupnost gilteritinibu